How the Target Hemoglobin of Renal Anemia Should Be?
Authors:
- Tetsuhiro TanakaTTTetsuhiro Tanaka
- Masaomi NangakuMNMasaomi Nangaku
- 19 September 2015
- journal article
- research article
- Published by S. Karger AG in Nephron
- Vol. 131 (3) , 202-209
Abstract
Renal anemia is caused by the deficiency of endogenous erythropoietin (Epo) due to renal dysfunction. We think that it is possible to slow the progression of chronic kidney disease (CKD) in case we initiate Epo early in pre-dialysis patients, especially in the non-diabetic population. Erythropoiesis stimulating agent (ESA) treatments targeting mild anemia (10-12 g/dl) can decrease the risk of occurrence of cardiovascular disease (CVD) in patients with hypertension, diabetes mellitus and congestive heart failure. As the large randomized controlled trials such as Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta, Correction of Hemoglobin and Outcomes in Renal Insufficiency and Trial to Reduce Cardiovascular Events with Aranesp Thearpy in the Western countries suggested, we do not recommend high doses of ESA to achieve the target hemoglobin (Hb) level. The target Hb of >13 g/dl might lead to increase in the risk of CVD although maintaining a high Hb of >12 g/dl without ESA is not harmful for CKD patients. It is desirable to determine the target Hb in dialysis patients depending on their ages. Renal anemia should be monitored constantly to start ESA and iron replacement therapy at an appropriate time, while avoiding their excess in order to minimize the occurrence of CVD and other complications. Taken all the international guidelines and our clinical experiences together, we should consider administration of ESA when the Hb level becomes <11 g/dl in pre-dialysis patients and <10 g/dl in dialysis patients.Keywords
This publication has 43 references indexed in Scilit:
- Intravenous Ferric Chloride Hexahydrate Supplementation Induced Endothelial Dysfunction and Increased Cardiovascular Risk among Hemodialysis PatientsPLOS ONE, 2012
- Hemodialysis-associated Hemosiderosis in the Era of Erythropoiesis-stimulating Agents: A MRI StudyThe American Journal of Medicine, 2012
- Naturally Occurring Higher Hemoglobin Concentration Does Not Increase Mortality among Hemodialysis PatientsJournal of the American Society of Nephrology, 2011
- Serum Iron Markers Are Inadequate for Guiding Iron Repletion in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney DiseaseAnnals of Internal Medicine, 2010
- 2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney DiseaseTherapeutic Apheresis and Dialysis, 2010
- Iron Indices in Chronic Kidney Disease in the National Health and Nutritional Examination Survey 1988–2004Clinical Journal of the American Society of Nephrology, 2009
- Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomesKidney International, 2008
- Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Reversal of Anemia by Erythropoietin Therapy Retards the Progression of Chronic Renal Failure, Especially in Nondiabetic PatientsNephron, 1997